Enhanc3D Genomics, a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – GenLink3D [TM]. The financing was led by BGF and Parkwalk Advisors, with support from existing private investors and Bioqube Ventures.